SynthesisBMC cancer2026
Prognostic implications of PD-L1 expression in gastric cancer: systematic review and meta-analysis of studies published between 2018 and 2025.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic implications of PD-L1 expression in gastric cancer: systematic review and meta-analysis of studies published between 2018 and 2025.BMC cancer · 2026Pooled it
- Microsatellite instability combined with PD-L1 expression in prognosis of gastric cancer: an integrated analysis based on individual patient data.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death-ligand 1 (PD-L1) is widely used as a predictive biomarker for response to immune checkpoint inhibitors in gastric cancer (GC); however, its independent prognostic value for overall survival remains controversial. Differences in PD-L1 detection methods, scoring systems, and tumor immune microenvironment characteristics may contribute to inconsistent findings across studies. Therefore, this systematic review and meta-analysis aimed to evaluate the association between PD-L1 expression and overall survival in patients with GC.
methodsA systematic search of PubMed, Scopus, MEDLINE, and Web of Science was conducted to identify eligible studies published between January 2018 and December 2025. Cohort studies reporting hazard ratios (HRs) for overall survival in relation to PD-L1 expression assessed by immunohistochemistry were included. A random-effects meta-analysis was performed to estimate pooled effect sizes. Heterogeneity was assessed using the I2 statistic, and subgroup analyses were conducted according to PD-L1 assessment methods. Meta-regression analyses were performed to explore potential sources of heterogeneity. Study quality was evaluated using the Newcastle–Ottawa Scale, and the certainty of evidence was assessed using the GRADE approach.
resultsSeven retrospective cohort studies comprising 1,993 patients with GC were included in the analysis. PD-L1 expression was significantly associated with overall survival (HR = 1.70, 95% CI: 1.13–2.55), although the direction of the prognostic effect varied across studies (I2 = 69.1%). Studies using the combined positive score (CPS ≥ 1) demonstrated more consistent prognostic associations compared with those employing semi-quantitative scoring systems. Meta-regression analyses did not identify significant modifying effects of publication year, mean age, or sex distribution on the pooled estimates. The overall certainty of evidence was rated as moderate.
conclusionPD-L1 expression is associated with overall survival in GC; however, its prognostic implications appear to be context-dependent and influenced by methodological differences in PD-L1 assessment and tumor immune microenvironment characteristics. Standardization of PD-L1 evaluation methods and integration with molecular tumor subtypes may improve its prognostic utility in GC.
trial registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251249939 , identifier CRD420251249939.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.